Mastercard Inc (MA) Stock News

Main Street Capital (MAIN) declined 1.34% to $53.74, underperforming the broader market which gained 0.6%. The stock has lost 2.38% over the past month while the Finance sector declined 3.99%. The company is expected to report EPS of $1 (up 3.09% YoY) with revenue projected at $144.47 million (up 3.32% YoY). MAIN holds a Zacks Rank #3 (Hold) rating and trades at a Forward P/E of 13.45, a premium to its industry average of 7.4.

ADMA Biologics has attracted investor attention with shares returning +7.3% over the past month, outperforming the S&P 500's +1.4% gain. The company is expected to post earnings of $0.19 per share for the current quarter (+18.8% YoY) and $0.78 for the fiscal year (+30% YoY). However, with a Zacks Rank #3 (Hold) rating and consensus estimates remaining unchanged over the past month, the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers with a B grade on the Value Style Score.

Marathon Digital Holdings (MARA) has underperformed the broader market, declining 13.1% over the past month compared to the S&P 500's 1.4% gain. The company is expected to report losses for the current quarter and fiscal year, though analysts project a return to profitability next year with $1 EPS. With a Zacks Rank #3 (Hold) rating and an F valuation grade indicating premium pricing relative to peers, the stock is expected to perform in line with the broader market in the near term.

Taiwan Semiconductor Manufacturing (TSM), Entegris (ENTG), and MACOM Technology Solutions (MTSI) are highlighted as beneficiaries of strong AI infrastructure demand. All three companies hold Zacks Rank #2 (Buy) ratings, with TSM leading advanced chip production, ENTG supplying specialized materials for semiconductor manufacturing, and MTSI capitalizing on AI data center optical connectivity needs. Strong recent earnings and positive growth outlooks support continued momentum.

Humacyte, Inc. (HUMA) closed at $0.48, down 4.26% on a day when major market indices gained. The stock has declined 17.34% over the past month, underperforming the Medical sector. The company is expected to report an EPS of -$0.09 and revenue of $0.86 million in its upcoming earnings release. Humacyte currently holds a Zacks Rank of #4 (Sell), and its industry ranks in the bottom 28% of all industries.

Applied Materials (AMAT) has gained significant investor attention, returning +19.3% over the past month compared to the S&P 500's +0.8%. The chipmaking equipment maker shows strong fundamentals with expected earnings growth of +35.8% for the current fiscal year and +43.1% for the next fiscal year. The company has consistently beaten consensus estimates over the trailing four quarters. However, AMAT is trading at a premium valuation relative to peers, receiving an F grade on the Zacks Value Style Score. Despite the high valuation, the stock holds a Zacks Rank #2 (Buy) rating, suggesting potential near-term outperformance.

Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating.

Vallourec announces the appointment of Isabelle Quéméneur as Group Chief Digital and Information Officer, effective October 5, 2026. Quéméneur, previously Chief Technology Officer at Danone, joins Vallourec's Executive Committee to lead digital transformation initiatives focused on customer value creation and modernizing team operations in response to cybersecurity and AI challenges.

Vallourec announces the appointment of Isabelle Quéméneur as Director of Digital & IT Systems, effective October 5, 2026. She joins the Executive Committee and brings extensive experience from her previous role as CTO at Danone, along with a background in technology leadership at major international companies including Société Générale, AXA, and Sanofi.

NOMAD Power Solutions announced that its Special Meeting of Stockholders was adjourned on October 2, 2026, without conducting business. The meeting will reconvene on October 30, 2026, to allow additional time to finalize the Nasdaq listing filing following the merger with NOMAD Transportable Power Systems. The Board continues to recommend stockholders vote 'FOR' the proposals.

A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

A class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales.

Humacyte, Inc. (HUMA) stock declined 2.86% to $0.50, underperforming broader market gains. The stock has lost 13.23% over the past month. While the company expects EPS to improve 35.71% next quarter with revenue up 14.67%, full-year projections show earnings declining 53.85% despite revenue doubling. The stock holds a Zacks Rank #4 (Sell) rating, and its industry ranks in the bottom 27% of all sectors.

Dimensional Fund Advisors Ltd. has disclosed a position of 277,711 EUR 1 ordinary shares (0.59%) in RHI Magnesita NV as of September 30, 2026. The disclosure was made on October 1, 2026, in connection with a takeover-related filing. Dimensional also made concurrent disclosures regarding Vesuvius PLC. The fund advisor purchased 369 shares at 29.3988 GBP per unit during the disclosure period.

The Brink's Company has agreed to propose divestiture of its NoteMachine/TestLink UK business as a remedy following the UK's Competition and Markets Authority Phase 1 decision on its acquisition of NCR Atleos Corporation. The divestiture was already contemplated in financial metrics and does not impact the expected $200 million in annual run-rate cost synergies. The NCR Atleos acquisition remains on track to close in early Q1 2027, with multiple prospective buyers expressing strong preliminary interest in the divested business.

Byron Medical has launched Zumax, a range of advanced surgical microscopes across Australia and New Zealand. The product line includes three tiers (OMS 2050, OMS 2380 R2, and OMS 3000) featuring true-colour illumination, integrated 4K documentation, ergonomic design, and smart digital integration for dental practices.

Main Street Capital (MAIN) closed at $55.94, up 1.58% and outperforming the S&P 500's 0.17% decline. The stock has declined 6.53% over the past month. Upcoming earnings are projected at $1 EPS (up 3.09% YoY) with revenue of $144.47 million (up 3.32% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 13.6, trading at a premium to its industry average of 7.78.

OneMain Financial, a consumer lending company with 1,400+ branches across 44 states, suffered a data breach in May 2026 that exposed names, addresses, and Social Security numbers of at least 16,988 individuals across multiple states. The breach was disclosed to authorities in September 2026. Edelson Lechtzin LLP is investigating potential class action claims to determine if the company failed to implement adequate cybersecurity safeguards.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about expected July 1, 2026 coverage, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Applied Materials (AMAT) has an average brokerage recommendation of 1.46 (Strong Buy/Buy) from 37 firms, with 73% Strong Buy ratings. However, the article cautions that brokerage recommendations often carry positive bias due to vested interests. The company's Zacks Rank #2 (Buy) rating is based on a 0.5% increase in consensus earnings estimates to $12.78, suggesting analyst optimism about near-term price movement.

Rosen Law Firm announces class action securities lawsuits against ARS Pharmaceuticals (SPRY) and Datavault AI (DVLT), with October 5, 2026 deadline for investors to join. ARS Pharmaceuticals is accused of providing misleading statements regarding insurance coverage expansion timeline for its epinephrine spray product neffy through CVS Caremark, allegedly causing investors to purchase shares at artificially inflated prices.

Marathon Digital Holdings (MARA) closed at $13.63, up 2.64% on the day. The stock has gained 18.78% over the past month, outperforming the S&P 500. However, analysts expect declining earnings and revenue, with full-year EPS forecast at -$5.25 per share (down 42.28% YoY) and revenue projected at $795.44 million (down 12.31% YoY). The Zacks Consensus EPS estimate has declined 33.6% over the past month, and the stock holds a Zacks Rank of #3 (Hold).

Applied Materials (AMAT) closed at $472.46, up 1.77% in the latest session. The company is expected to report earnings on November 12, 2026, with analysts projecting $4.05 EPS (86.64% YoY growth) and $10.29B quarterly revenue (51.28% YoY growth). AMAT holds a Zacks Rank #2 (Buy) with a Forward P/E of 36.31, slightly above its industry average of 36.01.

A securities class action lawsuit has been filed against ARS Pharmaceuticals (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about a July 1, 2026 coverage start date, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

GlobalFoundries (GFS) has partnered with SMART Photonics to combine silicon and indium phosphide photonics manufacturing capabilities. The company reported 62% year-over-year revenue growth in communications infrastructure and data center in Q2 2026, driven by strong AI and optical networking demand. GFS is advancing 1.6-terabit and 3.2-terabit optical modules while producing 200-gigabit-per-lane technology, though financial contributions from the SMART partnership will take time to materialize.

Hitachi Rail announced the launch of 'Enhanced by HMAX', a digital asset management platform embedding AI and real-time data capabilities across rolling stock, signaling, infrastructure and operations. The company committed to equipping all new rolling stock with HMAX sensor technology from 2027, with approximately 2,500 trains currently equipped and expanding to 3,500 in coming years. The platform enables predictive maintenance and operational optimization, with real-world deployments showing 15% reductions in maintenance costs and energy consumption.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing misleading statements to investors regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company reportedly made confident statements about July 1, 2026 coverage while concealing material adverse facts, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

In a comparison of two foreign banks for value investors, Banco Macro (BMA) emerges as the more attractive option with a Zacks Rank of #1 (Strong Buy) and a Value grade of A, compared to National Australia Bank Ltd. (NABZY) which has a Zacks Rank of #3 (Hold) and a Value grade of D. BMA trades at a forward P/E of 9.10 versus NABZY's 18.42, and has a lower PEG ratio of 0.34 compared to 5.92, indicating better valuation metrics.

In a comparison of two Technology Services sector stocks, Amadeus IT Group SA (AMADY) emerges as the superior value option over Amplitude Inc. (AMPL). AMADY has a Zacks Rank of #2 (Buy) with a forward P/E of 15.45 and Value grade of B, while AMPL has a Zacks Rank of #3 (Hold) with a forward P/E of 207.98 and Value grade of F. AMADY's stronger earnings outlook and more attractive valuation metrics make it the better choice for value investors.

Applied Materials (AMAT) and Lam Research (LRCX) are compared as investment picks in the wafer fabrication equipment market. AMAT benefits from AI-driven demand across foundry-logic, DRAM, and advanced packaging, with strong revenue growth and a broader portfolio. LRCX also benefits from AI investment but faces material risks from China trade restrictions, which accounted for 26% of recent revenues. Both stocks carry Zacks Rank #2 (Buy) ratings, though AMAT is positioned as the safer pick due to its diversified portfolio.